TNM stage I colorectal cancer is commonly characterized by a good prognosis, with 5-year survival of around 80% to 90%. Nonetheless, disease progression occurs in a percentage of cases, although the causes of an adverse clinical course still remain to be clarified. In the present study, we analyzed and compared the immunohistochemical expression of neutrophil gelatinase-associated lipocalin, an iron-binding protein, which is involved in colorectal cancer progression, in series a of 29 surgically resected colorectal carcinomas obtained from patients who died of the disease and in a cohort of 22 colorectal cancers from patients alive 5 years after the initial diagnosis. The prognostic value of neutrophil gelatinase-associated lipocalin expression on the overall survival to colorectal cancer was investigated. Variable neutrophil gelatinase-associated lipocalin immunoexpression was demonstrated in 23 of the 51 analyzed cases, with a significantly higher frequency of positive cases among patients who died of the disease. Moreover, neutrophil gelatinase-associated lipocalin expression appeared to be a significant independent negative prognostic marker related to shorter overall survival in stage I colorectal carcinoma. If our findings are confirmed in further analyses, neutrophil gelatinase-associated lipocalin assessment might be used to select patients with a higher risk of progression and to find adjuvant therapies for the prevention of adverse outcomes. © 2011 Elsevier Inc.

Neutrophil gelatinase-associated lipocalin: A new prognostic marker in stage i colorectal carcinoma? / Barresi, Valeria; Di Gregorio, Carmela; Reggiani-Bonetti, Luca; Ieni, Antonio; Ponz-De Leon, Maurizio; Barresi, Gaetano. - In: HUMAN PATHOLOGY. - ISSN 0046-8177. - 42:11(2011), pp. 1720-1726. [10.1016/j.humpath.2010.05.031]

Neutrophil gelatinase-associated lipocalin: A new prognostic marker in stage i colorectal carcinoma?

Di Gregorio, Carmela;Reggiani-Bonetti, Luca;Ponz-De Leon, Maurizio;
2011

Abstract

TNM stage I colorectal cancer is commonly characterized by a good prognosis, with 5-year survival of around 80% to 90%. Nonetheless, disease progression occurs in a percentage of cases, although the causes of an adverse clinical course still remain to be clarified. In the present study, we analyzed and compared the immunohistochemical expression of neutrophil gelatinase-associated lipocalin, an iron-binding protein, which is involved in colorectal cancer progression, in series a of 29 surgically resected colorectal carcinomas obtained from patients who died of the disease and in a cohort of 22 colorectal cancers from patients alive 5 years after the initial diagnosis. The prognostic value of neutrophil gelatinase-associated lipocalin expression on the overall survival to colorectal cancer was investigated. Variable neutrophil gelatinase-associated lipocalin immunoexpression was demonstrated in 23 of the 51 analyzed cases, with a significantly higher frequency of positive cases among patients who died of the disease. Moreover, neutrophil gelatinase-associated lipocalin expression appeared to be a significant independent negative prognostic marker related to shorter overall survival in stage I colorectal carcinoma. If our findings are confirmed in further analyses, neutrophil gelatinase-associated lipocalin assessment might be used to select patients with a higher risk of progression and to find adjuvant therapies for the prevention of adverse outcomes. © 2011 Elsevier Inc.
42
11
1720
1726
Neutrophil gelatinase-associated lipocalin: A new prognostic marker in stage i colorectal carcinoma? / Barresi, Valeria; Di Gregorio, Carmela; Reggiani-Bonetti, Luca; Ieni, Antonio; Ponz-De Leon, Maurizio; Barresi, Gaetano. - In: HUMAN PATHOLOGY. - ISSN 0046-8177. - 42:11(2011), pp. 1720-1726. [10.1016/j.humpath.2010.05.031]
Barresi, Valeria; Di Gregorio, Carmela; Reggiani-Bonetti, Luca; Ieni, Antonio; Ponz-De Leon, Maurizio; Barresi, Gaetano
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1154250
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 8
social impact